Aldeyra Therapeutics Inc.
| NASDAQ: ALDX |
| Healthcare / Biotechnology / USA |
| 3.99 | +0.1200 | +3.10% | Vol 760.90K | 1Y Perf -67.53% |
| Jun 28th, 2022 16:00 DELAYED |
| BID | 3.65 | ASK | 4.10 | ||
| Open | 3.95 | Previous Close | 3.87 | ||
| Pre-Market | - | After-Market | 3.87 | ||
| - - | -0.12 -3.01% |
| Target Price | 16.60 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 316.04 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 16.93 | Earnings Rating | Sell | |
| Market Cap | 232.62M | Earnings Date | 4th Aug 2022 | |
| Alpha | 0.00 | Standard Deviation | 0.24 | |
| Beta | 1.64 |
Today's Price Range 3.874.04 | 52W Range 2.3612.01 | 5 Year PE Ratio Range -4.50-3.90 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 21.70% | ||
| 1 Month | 24.84% | ||
| 3 Months | -25.15% | ||
| 6 Months | -4.68% | ||
| 1 Year | -67.53% | ||
| 3 Years | -35.50% | ||
| 5 Years | -14.00% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -44.94 | |||
ROE last 12 Months | -40.86 | |||
ROA (5Y Avg) | -16.88 | |||
ROA last 12 Months | -34.98 | |||
ROC (5Y Avg) | -53.49 | |||
ROC last 12 Months | -35.55 | |||
Return on invested Capital Q | -7.70 | |||
Return on invested Capital Y | -6.74 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.30 | ||||
| 1.13 | ||||
| - | ||||
| - | ||||
| -5.10 | ||||
| -0.73 | ||||
| 1.13 | ||||
| 3.27 | ||||
| 13.57M | ||||
| Forward PE | -2.20 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.30 | ||||
| 13.60 | ||||
| 0.08 | ||||
| 0.08 | ||||
| -37.00 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.31 | -0.29 | 6.45 |
| Q04 2021 | -0.31 | -0.27 | 12.90 |
| Q03 2021 | -0.29 | -0.27 | 6.90 |
| Q02 2021 | -0.27 | -0.28 | -3.70 |
| Q01 2021 | -0.29 | -0.25 | 13.79 |
| Q04 2020 | -0.26 | -0.35 | -34.62 |
| Q03 2020 | -0.28 | -0.23 | 17.86 |
| Q02 2020 | -0.34 | -0.25 | 26.47 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.32 | -3.23 | Negative |
| 9/2022 QR | -0.34 | -6.25 | Negative |
| 12/2022 FY | -1.37 | -3.79 | Negative |
| 12/2023 FY | -1.67 | -20.14 | Negative |
| Next Report Date | 4th Aug 2022 |
| Estimated EPS Next Report | -0.32 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 760.90K |
| Shares Outstanding | 58.30K |
| Shares Float | 47.36M |
| Trades Count | 5.76K |
| Dollar Volume | 3.00M |
| Avg. Volume | 1.49M |
| Avg. Weekly Volume | 2.14M |
| Avg. Monthly Volume | 1.43M |
| Avg. Quarterly Volume | 908.13K |
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) stock closed at 3.87 per share at the end of the most recent trading day (a 5.16% change compared to the prior day closing price) with a volume of 1.05M shares and market capitalization of 232.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Aldeyra Therapeutics Inc. CEO is Todd C. Brady.
The one-year performance of Aldeyra Therapeutics Inc. stock is -67.53%, while year-to-date (YTD) performance is -3.25%. ALDX stock has a five-year performance of -14%. Its 52-week range is between 2.355 and 12.01, which gives ALDX stock a 52-week price range ratio of 16.93%
Aldeyra Therapeutics Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.98%, a ROC of -35.55% and a ROE of -40.86%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aldeyra Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Aldeyra Therapeutics Inc.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Aldeyra Therapeutics Inc. is Strong Buy (1), with a target price of $16.6, which is +316.04% compared to the current price. The earnings rating for Aldeyra Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aldeyra Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aldeyra Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.30, ATR14 : 0.30, CCI20 : 143.71, Chaikin Money Flow : 0.04, MACD : 0.13, Money Flow Index : 75.23, ROC : 10.57, RSI : 63.17, STOCH (14,3) : 83.16, STOCH RSI : 1.00, UO : 59.01, Williams %R : -16.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aldeyra Therapeutics Inc. in the last 12-months were: Martin J. Joyce (Buy at a value of $15 025), Todd C. Brady (Buy at a value of $59 546)
Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
CEO: Todd C. Brady
Telephone: +1 781 761-4904
Address: 131 Hartwell Avenue, Lexington 02421, MA, US
Number of employees: 11
TipRanks News for ALDX
Wed, 25 May 2022 03:45 GMT Aldeyra Therapeutics (ALDX) Received its Third Buy in a Row
- TipRanks. All rights reserved.Mon, 23 May 2022 10:25 GMT Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Equillium (EQ) and Stealth Biotherapeutics (MITO)
- TipRanks. All rights reserved.Wed, 30 Mar 2022 03:06 GMT Analysts Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Axsome Therapeutics (AXSM)
- TipRanks. All rights reserved.
